Prevalence of Metabolic Syndrome in Psoriasis Patients and its Relation to Disease Duration: A Hospital Based Case-Control Study

Praveenkumar, Udayakumar; Ganguly, Satyaki; Ray, Lopamudra; Nanda, Saurav Narayan; Kuruvila, Sheela

doi:10.7860/jcdr/2016/17791.7218

Cited by 42 publications

(43 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Another two studies from Pondicherry are also in concordance with our observations. 10,14 But this is in contrast to the study by Zindancı I et al from Turkey. 6 Regarding distribution pattern of psoriatic cases, in our study out total 50 cases, 39 had psoriasis vulgaris, 6 had psoriatic erythroderma and 4 patients had palmoplantar psoriasis and one patient had acute generalized pustular psoriasis.…”

Section: Discussioncontrasting

confidence: 55%

“…This observation is in agreement with many studies, which have shown a significantly higher prevalence of metabolic syndrome among psoriasis patients compared to controls. 6,10,14 However, this finding may not be comparable with the investigations done in different geographical milieu viz. Bangalore, Kashmir and Mumbai, as they did not use the Asian modification for waist circumference.…”

Section: Discussioncontrasting

confidence: 51%

See 1 more Smart Citation

Metabolic syndrome in patients with chronic plaque psoriatic disease: a case-control study from western Uttar Pradesh, India

Jain

Singh

et al. 2018

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Various studies on psoriasis and metabolic syndrome have shown a large variation in their results. An increasing frequency is imposing a substantial burden on the overall health of psoriasis patients that needs to be appropriately foreseen and addressed. Aim of this study was to study various aspects of metabolic syndrome in patients with chronic plaque psoriatic disease in northern Indian region.Methods: A cohort of patients registering for treatment of chronic plaque psoriasis at Dermatology outpatients’ department formed the study population. Detailed history was captured. General physical examination was carried out. A thorough cutaneous examination was undertaken which captured details on type, distribution and arrangement of primary lesions and secondary changes in patients. After overnight fasting, venous blood samples were collected from the subjects and were analysed for serum glucose, triglyceride and HDL-cholesterol. Results: Metabolic syndrome in psoriasis was associated with higher age. Gender wise male preponderance was observed. Among the psoriasis cases, 64% had metabolic syndrome whereas among the control subjects 48% had the condition (p-value 0.158). The mean for serum triglyceride level for psoriasis patients (159.42 mg/dL) was higher than controls (144.25 mg/dL). Forty six percent of cases fulfilled elevated triglycerides ≥150 mg/dl as a criterion of metabolic syndrome, compared to 40% of controls. Conclusions: We observed a higher frequency of metabolic syndrome among psoriasis cases in a northern Indian population. An association of dyslipidemia with psoriasis was also noted. Routine screening of the condition to facilitate early diagnosis and treatment should be undertaken.

show abstract

Section: Discussioncontrasting

confidence: 55%

Section: Discussioncontrasting

confidence: 51%

Metabolic syndrome in patients with chronic plaque psoriatic disease: a case-control study from western Uttar Pradesh, India

Jain

Singh

et al. 2018

Int J Res Med Sci

View full text Add to dashboard Cite

show abstract

“…In contrast, we could not confirm this correlation in our study. In comparison with data from the literature, we partly recorded lower rates of comorbid diseases in our series [35][36][37] . An explanation for the lower rates detected may be that 64.8% of the patients received Fumaderm ® as a first-line therapy, which means that the patients were in comparatively early stages of the disease.…”

Section: Discussionmentioning

confidence: 85%

“…An explanation for the lower rates detected may be that 64.8% of the patients received Fumaderm ® as a first-line therapy, which means that the patients were in comparatively early stages of the disease. It is well known that the rate of comorbidity increases with severity of psoriasis [36,37] .…”

Section: Discussionmentioning

confidence: 99%

Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters

Sondermann

Rompoti²,

Leister³

et al. 2017

Dermatology

View full text Add to dashboard Cite

Background: Fumaric acid esters (FAEs) are a broadly used therapy option for patients suffering from moderate-to-severe plaque psoriasis. Various studies in psoriasis have already shown peripheral blood lymphopenia during oral FAE therapy. Smaller studies also documented a reduction of CD4+ and CD8+ cell counts. Up to now, there are few case reports on opportunistic infections under FAE therapy - all of them associated with lymphopenia. Objective: To examine the influence of FAEs on white blood cells with special regard to leukocytes, lymphocytes, and CD4+ and CD8+ cells during psoriasis therapy. Patients and Methods: A cohort of 105 patients with diagnosed moderate-to-severe chronic plaque psoriasis was enrolled in this single-centre observational trial. For a cohort of 36 patients, T-cell subset analyses were performed. Results: Of the total, 65 patients were male (61.9%) and 40 (38.1%) female; the mean age was 43.3 years (range 16-73 years). The median lymphocyte count was significantly reduced by about 35.8% after the first 6 months of therapy. When assessing the lymphocyte count nadir over the whole period observed, 46.7% of the patients developed lymphopenia. Severe lymphopenia (<500/µL) was documented in 11.4% of the patients. The CD4+ and CD8+ cell counts were significantly reduced by about 30.2 and 45.3%, respectively. Conclusion: To the best of our knowledge this is the largest clinical investigation analysing prospectively CD4+ and CD8+ cell counts in psoriasis patients receiving FAEs. We suggest periodic monitoring of absolute lymphocyte counts as well as the establishment of the determination of T-cell subsets prior to and during therapy.

show abstract

“…Recently, psoriasis has been recognized as a systemic disease associated with multiple comorbidities [4–6], including Crohn's disease, ulcerative colitis, diabetes, chronic neuropathy, depressions, lymphomas, multiple sclerosis, malignant processes, especially lymphoproliferation and nonmelanoma skin cancers, metabolic syndrome (MS) [7, 8], and cardiovascular diseases, such as hypertension, myocardial infarction, and stroke [9]. For comorbidity and mainly for the increased risk of cardiovascular disease, the risk of shortening the life of psoriatic patients is 5 years [10].…”

Section: Introductionmentioning

confidence: 99%

Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients

Vachatova

Andrýs

Krejsek

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

The presented article studies the role of selected inflammatory and anti-inflammatory serum markers of psoriatic patients in the pathogenesis of metabolic syndrome (MS) and psoriasis. The study is based on the comparison between the group of psoriatic patients (74) and the control group (65). We found significantly higher BMI (p < 0.05) and diastolic blood pressure (p < 0.05) in the psoriatic patients. The values of waist circumference and BMI were significantly higher (p < 0.05) in the male patients compared to the men in the control group. The analysis revealed significantly higher CRP (p < 0.001), Lp-PLA2 (p < 0.001), leptin (p < 0.01), and resistin (p < 0.01) levels in the psoriatic patients. Significantly higher levels of CRP (p < 0.01), Lp-PLA2 (p < 0.001), leptin (p < 0.01), and resistin (p < 0.05) were found in the patients with MS compared to the controls with MS. The level of adiponectin was significantly lower (p < 0.01) in the patients with MS. Finally, we found significantly higher level of Lp-PLA2 (p < 0.001) in the group of patients without MS compared to the controls without MS. In conclusion, observed inflammatory and anti-inflammatory markers (CRP, adiponectin, leptin, resistin, and Lp-PLA2) are involved in both pathogenesis of MS and pathogenesis of psoriasis. The level of Lp-PLA2 indicates the presence of subclinical atherosclerosis (cardiovascular risk) in psoriatic patients.

show abstract

Prevalence of Metabolic Syndrome in Psoriasis Patients and its Relation to Disease Duration: A Hospital Based Case-Control Study

Cited by 42 publications

References 26 publications

Metabolic syndrome in patients with chronic plaque psoriatic disease: a case-control study from western Uttar Pradesh, India

Metabolic syndrome in patients with chronic plaque psoriatic disease: a case-control study from western Uttar Pradesh, India

Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters

Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients

Contact Info

Product

Resources

About